Officials said, that people must wait till 2021 first quarter in order to get vaccine working and get all healed. According to them this is the shortest possible time to get vaccine practically ready. The news comes days after the Parliamentary standing committees had begun to resume work after a long spell of hibernation.
Covaxin or COVID – 19 Vaccine is going to be developed by Government’s Medical Research body, Indian Council of Medical Research (ICMR). They targeted to get the vaccine working by 15th of august, however now it had to be delayed for practical use.
Indian Government’s Principal Scientific Advisor – Professor Krishnaswamy VijayRaghavan, was present in the meeting. Representatives of Council of Scientific and Industrial Research (CSIR), the Department of Science and Technology and the Department of Biotechnology were also present.
ICMR clarified that, “it was all, meant to cut unnecessary red tape, without bypassing any necessary process, and speed up recruitment of participants”.
Members of committe were believed to have raised specific questions about recent claims made by yoga guru Ramdev who launched Coronil, claiming it can treat coronavirus, only to retract later.
Meanwhile, researchers in India are all set to start human trials of India’s first indigenous coronavirus vaccine candidate – COVAXIN.
Seniors & Officials at the comitee told that they are hopeful and optimistic about India’s chances of inventing the vaccine that will be able to treat Corona Virus. This Committee was led by Congress MP Jairam Ramesh.
Bharat Biotech MD Dr Krishna Ella, tells Times Now Digital why he believes COVAXIN, India’s first indigenous coronavirus vaccine, created by the firm will work against the SARS-CoV-2
Hyderabad: Earlier this week, COVAXIN developed by leading vaccine maker Bharat Biotech in collaboration with the Indian Council of Medical Research and the National Institute of Virology (NIV), became India’s first indigenous vaccine against the novel coronavirus now called the SARS-CoV-2 to get the approval for human clinical trials from the drug regulator. The Hyderabad-based biotech firm has been given the go-ahead by the DCGI to conduct phase 1 and 2 clinical trials of its COVID-19 vaccine candidate after preclinical studies demonstrated safety and effective immune response.